LJMU Research Online

**Barrie, A, McDowell, G and Troup, S**

**An investigation into the effect of potential confounding patient and treatment parameters on human embryo morphokinetics.**

**http://researchonline.ljmu.ac.uk/id/eprint/14469/**

**Article**

**Citation** (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

**Barrie, A, McDowell, G and Troup, S (2021) An investigation into the effect of potential confounding patient and treatment parameters on human embryo morphokinetics. Fertility and Sterility. ISSN 0015-0282**

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

http://researchonline.ljmu.ac.uk/

**Title Page** *F&S31158 decline and resubmit*

**Running title: Confounders of an embryo's morphokinetic profile**

# Title: An investigation into the effect of potential confounding patient and treatment parameters on an embryo's morphokinetic profile

**Authors: Amy Barrie[1], PhD, Garry McDowell[2], PhD, Stephen Troup[3], PhD**

1) CARE Fertility Chester, Countess Chester Hospital, Chester, CH2 1UL
2) Manchester Metropolitan University, Minshull House, 47-49 Chorlton Street, Manchester, M1 3FY
3) Association of Reproductive Clinical Scientists, Profile Productions, Boston House, 69-75 Boston Manor Road, Brentford, TW8 9JJ

**Email addresses for all authors:**
Amy Barrie, PhD: amy.barrie@carefertility.com
Garry McDowell, PhD: g.mcdowell@mmu.ac.uk
Stephen Troup, PhD: steve@rsc.me.uk

**Corresponding author:**
Amy Barrie, PhD
CARE Fertility Chester
First Floor Women and Children's Building
Countess of Chester Hospital
Chester
CH2 1UL

## Capsule
Embryo morphokinetics are subtly affected by patient and treatment parameters exhibiting complex relationships rather than a systemic effect, as analysed using multiple regression on 2376 embryos from 639 patients.

## Keywords
Embryo culture, embryo viability, reproductive technology

## Abstract
Objective: To determine the effect of patient and treatment parameters on nineteen embryo morphokinetic parameters using pronuclear fading as time-zero.
Design: Single-site, retrospective cohort analysis
Setting: Fertility treatment centre
Patients/Animals: Patients undergoing treatment between September 2014 and January 2016 (n=639) whose embryos were cultured in the EmbryoScope® for six days (n=2376).
Intervention(s): None
Main Outcome Measure(s): Multiple regression analysis of body mass index, maternal age, infertility diagnosis, treatment type, suppression protocol on time to each cellular division (tn); t2, t3, t4, t5, t6, t7, t8, t9, time to start of compaction (tM), start of blastulation (tSB), full blastocyst (tB) and interval measurements; s2, s3, cc2, cc3, cc4, t9-tM, tM-tSB and tSB-tB. Multiple regression results were considered

significant at $p<0.05$ and beta coefficients were analysed to quantify any significant effects.
Results: Embryos appeared to be subtly affected by patient and treatment parameters, exhibiting complex relationships between various morphokinetic parameters and specific patient and treatment factors, rather than a systemic effect.
Conclusion: These findings outline the need for the consideration of confounding factors when assessing an embryo's ability to achieve implantation. Although morphokinetic parameters have been related to embryo viability, it is likely that this will vary dependent on the embryo's origin.

## Introduction

Time-lapse imaging is no longer a novel technique for the culturing of human embryos. Time-lapse imaging is employed by many internationally and has gained a high degree of attention based on little scientific evidence (1). In theory, time-lapse systems (TLS) offer two potential benefits; a highly controlled, undisturbed culture environment and an increased level of detail when analysing the embryos contained within the system. However, a recent Cochrane review concluded that 'there is insufficient evidence of differences in live birth, miscarriage, still birth or clinical pregnancy to choose between TLS [time lapse systems] and conventional incubation' (1). It is notoriously difficult for clinics to perform the much-needed randomised controlled trials for a multitude of reasons; funding availability, lack of patient interest and difficulty in the approval process. As a result, many turn to retrospective, observational investigations to determine the relevance and significance of the environment and the information that TLS can provide, of which the pitfalls have been highlighted (2).

What does remain novel about TLS is not their use *per se*, in the simplest form, but how the information gleaned from them is put to use. Time-lapse systems can capture images of embryos every five minutes over a period of six days, generating thousands of images per embryo. The wealth of information available to the user regarding one embryo is, undeniably, substantial but exactly how to use this information is a problem posed and the reason this feature of TLS remains novel.

The correlation of morphokinetic data (the timings at which an embryo reaches a developmental milestone) provided by TLS with the embryo's ability to create a pregnancy both in humans and animals have been identified; the appearance and disappearance of pronuclei and nuclei at each cell stage (3-6) the length of time between early cytokineses (7-14) direct one to three cell divisions (15), and start times of blastulation (16), among others. With this information in tow, many pursued the development of embryo selection algorithms (ESAs). ESAs incorporate a set of instructions for the user where, depending on the answers to the questions asked, a score is given that will aid in the selection, or deselection, of embryos in any given cohort. Many ESAs have now been developed and published each using differing outcome parameters, exclusion and inclusion criteria and morphokinetic parameters to define the selection of an embryo (6, 12, 14, 16-22). Crucially, a number of these ESAs have been validated externally with varying degrees of success (23, 24).

Unfortunately, the lack of control for confounding variables in time-lapse investigations, especially those involving the derivation of ESAs, reduces their transferability meaning they are likely to be applicable only to the patients on which,

and environment in which, they were derived. The effect of confounders on seven embryo morphokinetics has previously been assessed to determine the effect of maternal age, treatment type, body mass index, cumulative gonadotrophin dose and the number of previous attempts (2). From this investigation, the authors conclude that the patient demographic rather than an embryos' viability when considered as part of a large cohort of embryos can explain a high degree of embryo timing variability. More recently, a new line of research has become apparent utilising machine learning to aid in the development of effective embryo selection methods (25-27). Still in its infancy, this method has significant promise to remove confounders and make embryo selection a relative and objective process.

The investigation presented here sought to determine the effects of a number of patient and treatment parameters on nineteen morphokinetic parameters using a multiple regression analysis methodology. The purpose of this investigation was to echo that previously found, to inform future directions of research, specifically the consideration of embryo origin during the derivation of embryo selection methodologies, and to highlight that the power of TLS lies beyond the human eye.

**Materials and Methods**

This investigation was a single site, retrospective observational design approved by the North West Research Ethics Committee (ref: 14/NW/1043) as well as gaining Institutional Review Board approval. All procedures and protocols complied with UK regulation (Human Fertilisation and Embryology Act, 1990, 2008). Data were obtained from 639 treatment cycles including 2376 embryos cultured in the EmbryoScope® incubators between September 2014 to January 2016 at the Hewitt Fertility Centre, Liverpool.

***Ovarian stimulation***

Pituitary down regulation was achieved either using a gonadotrophin releasing hormone agonist (buserelin, Suprecur®, Sanofi Aventis, UK) or antagonist (cetrorelix acetate, Cetrotide®, Merck Serono, Germany). Ovarian stimulation was performed using urine derived or recombinant follicle stimulating hormone (Progynova (Bayer, Germany), Fostimon, Merional (IBSA, Switzerland), Menopur® (Ferring Fertility, Switzerland), Gonal f® (Merck Serono). Doses were adjusted based on patient demographic and response. On identification of a lead follicle of 17mm and at least two more of 16mm, patients were given 5000IU of subcutaneous hCG (Gonasi® HP, IBSA Pharmaceuticals, Italy) 36 hours prior to oocyte collection. Luteal support was provided using 400mg of progesterone pessaries twice daily (Cyclogest®, Actavis, UK) until the pregnancy test was performed.

***Oocyte retrieval and embryology***

Ultrasound guided oocyte collection was performed transvaginally under sedation (Diprivan, Fresenius Kabi, USA). Collected oocyte cumulus complexes were cultured in 4 well dishes (Nunc™, Thermo Scientific, USA) each well containing 0.65ml GIVF™ (Vitrolife, Gothenburg, Sweden) covered with 0.35ml OVOIL™ (Vitrolife) in a standard incubator (Sanyo Multigas MCO 18M). Sperm preparation was performed using a standard gradient separation (ISolate®, Irvine Scientific, USA) at 0.3 relative centrifugal force (rcf) for ten minutes followed by two washes at 0.6rcf for ten minutes using GIVF™. Those oocytes destined for ICSI were prepared using enzymatic (HYASE 10X™, Vitrolife) and mechanical digestion. ICSI was performed

on all metaphase II oocytes (MII) approximately four hours following collection after which time all injected oocytes were placed in individual culture drops of GTL™ (Vitrolife) and cultured in the EmbryoScope® (Vitrolife). Those oocytes destined for standard insemination (IVF) had this performed approximately four hours after collection and were replaced into a standard incubator until fertilisation check the following day. Oocytes were then checked for fertilisation approximately 16 to 18 hours post insemination (hpi) and all fertilised oocytes along with all unfertilised metaphase II oocytes were placed in individual culture drops as with ICSI derived embryos and cultured in the EmbryoScope®. Embryo selection was performed using the national grading scheme (ACE/BFS guidelines (28)) along with an internally derived ESA. The ESA employed was used as an additive to morphology with the latter remaining the gold standard. Embryo transfer was performed using the highest-grade embryo(s) either five days post collection. Selected embryos were cultured in EmbryoGlue® (Vitrolife) for 10 to 30 minutes in a standard incubator prior to embryo transfer. Embryos were cultured at 37°C, 6% $CO_2$, 5% $O_2$, 89% $N_2$ throughout. Where applicable, supernumerary embryos were cultured until day five or day six for a decision regarding cryopreservation.

***Analysis of time-lapse information***

The image interval on the EmbryoScope® was set to ten minutes with seven focal planes. Images were collected for the duration of culture immediately following ICSI or fertilisation check (for IVF derived embryos) to utilisation. Annotation was performed manually as part of the clinical workload in the embryology laboratory using definitions previously described (29). Consistency of annotations was confirmed by participation of each embryologist in an internal quality assurance scheme. Time-zero (t0) was assigned as pronuclei fading to eliminate the ambiguity regarding using time of insemination or injection. The absolute morphokinetic parameters assessed included time to two-cell (t2), three-cell (t3), four-cell (t4), five-cell (t5), six-cell (t6), seven-cell (t7), eight-cell (t8), nine-cell (t9), time to start of compaction (tM), start of blastulation (tSB) and full blastocyst (tB). The interval morphokinetic parameters assessed included the time between t2 and t3 (cc2), t4 and t5 (cc3), t8 and t9 (cc4), t3 and t4 (s2), t5 to t8 (s3), t9 and tM, tM and tSB, tSB and tB.

***Outcome measures and statistical analysis***

A multiple regression was performed on 2376 embryos to determine the effect on t2, t3, t4, t5, t6, t7, t8, t9, tM, tSB, tB, cc2, cc3, cc4, s2, s3, t9-tM, tM-tSB and tSB-tB of maternal age, maternal BMI, suppression protocol and primary infertility diagnosis. All morphokinetic parameters were classed as continuous, dependent variables. Maternal age and BMI were classed as continuous, independent variables. Treatment type, primary diagnosis and suppression protocol were categorical independent variables. However, because treatment type and infertility diagnosis were polytomous they required the use of a reference category for statistical analysis. The reference category for treatment type was IVF and the reference category for infertility diagnosis was male factor. As was the case for all morphokinetic parameters, linearity was assessed by partial regression plots and a plot of studentised residuals against the predicted values. There was independence of residuals, as assessed by a Durbin-Watson statistic (1.00-2.00). There was homogeneity of variance, as assessed by visual inspection of a plot of studentised residuals versus unstandardised predicted values. There was no evidence of

multicollinearity (where one variable can be linearly predicted from others), as assessed by tolerance values greater than 0.1. No studentised deleted residuals were excluded from the analysis as they did not have advantage values greater than 0.2 and values for Cook's distance above one. The assumption of normality was met, as assessed by Q-Q Plot. Results were considered significant at $p<0.05$. Statistical analysis was performed using the statistical package SPSS (IBM corporation, 2015).

## Results

In total, 2376 embryos from 639 patients were included in this analysis. None of the patient or treatment parameters affected the morphokinetics of embryo development as a whole (table 1 and 2). Instead, complex relationships appeared to exist between specific morphokinetic parameters and patient and treatment parameters. Of all assessed parameters, suppression protocol (agonist or antagonist) had no significant effect on any morphokinetic parameter. Maternal age significantly affected t2, t4, tB and tM-tSB. Female patient BMI affected t2 alone. In addition, those embryos created using ICSI (excluding those utilising donor sperm) had significantly different t2, tSB, tB, cc2 and tM-tSB measurements compared to those created using IVF.

Beta coefficients, indicating the amount of change elicited by the dependent variable (morphokinetic parameter) when a one-unit change in the independent variable is made (patient or treatment characteristics), were also assessed. Concerning maternal age, an increase of one year results in a decrease in t2 by 0.006 hours (h) (equivalent to 21.6 seconds (s)), t4 by 0.029h (equivalent to 1.74 minutes (m)), an increase in tB by 0.78h and an increase in tM-tSB by 0.92h. This result indicates that embryos from younger patients undergo t2 and t4 slower than those from older patients however are overall faster than older counterparts. Furthermore, where ICSI treatment has been performed (excluding donor sperm) embryos undergo t2 0.098h (equivalent to 5.88m) earlier, tSB 1.157h later and tB 1.510h later than those undergoing IVF. Embryos derived from ICSI also have significantly longer cc2 (by 0.185h) and tM-tSB (by 0.637h). This result indicates that embryos derived from ICSI undergo the first cleavage of preimplantation embryo development earlier than those undergoing IVF however by the blastocyst stage of development ICSI embryos are overall slower than those derived from IVF.

When assessing causes of infertility and treatment type, seven categories were identified that had less than twenty patients in each; use of donor sperm, endocrine cause of infertility, secondary cause of infertility, IMSI, TESE-ICSI, D-IVF and D-ICSI. Statistical significance was found when analysing the data however, these will not be discussed at length owing to the sample size and likelihood of statistical insignificance should the sample size be increased. These results do allude to a need for further investigation with larger sample sizes and so remain in the overall dataset for observation. Baseline characteristics of the patient cohort are shown in table 3.

## Discussion

The effect of patient and treatment parameters on nineteen morphokinetic parameters was assessed using a large group of embryos from an unselected cohort of patients. Using a defined time-point as t0, a number of complex relationships

between specific patient and treatment parameters and certain morphokinetic parameters was revealed. The analysis presented adds to the results seen by others (2) and together with these highlight the presence of confounders when considering morphokinetics confirming that machine learning should be the focus of future research when considering time-lapse systems for embryo selection.

Maternal age significantly affected four morphokinetic parameters; t2, t4, tB and tM-tSB demonstrating that embryos from younger patients undergo t2 slower than those from older patients however are, overall, faster. Although the evidence is lacking in the literature regarding the specific relationship between morphokinetic parameters and maternal age, aneuploidy could be used as a proxy. It is well accepted that the rate of aneuploidy increases with maternal age (30) and a particular investigation observed significant differences in blastulation morphokinetic parameters and risk of aneuploidy as determined through trophectoderm biopsy (16). From this investigation, a risk classification model was developed and, although when externally applied lost efficacy (23, 24), supports the notion that patient age, perhaps more specifically embryo ploidy, affects morphokinetic parameters. Of particular interest is the use of both tSB and tB in the classification model outlined by Campbell et al. In the results presented here, tM-tSB and tB were both delayed in patients of increased maternal age. This is mirrored in the timings proposed by Campbell et al where those embryos carrying a medium risk of aneuploidy were more likely to reach the start of blastulation later (>96.2 hours post insemination (hpi)) and those with a high risk were likely to reach tB later (>122.9hpi). Others have investigated the effect of maternal age with similar findings. In 2014, the correlation between maternal age and a number of morphokinetic timings; t5, cc2, cc3. s2 and t5-t2 was assessed (31). Although there was no statistically significant difference in these parameters in embryos from younger and older patients, there was a trend towards those from older patients being delayed in development. In 2016, time-lapse images of 1730 biopsied embryos were analysed, a correlation between ploidy and blastulation parameters was detected where aneuploid embryos were delayed in development compared to euploid counterparts (32). Further to this, the effect of maternal age on morphokinetic parameters was investigated using a similar study design to that presented here (2). In this investigation, embryos were seen to reach tSB 0.29h later with each one-unit increase in maternal age. The size of the time differences presented here may indicate a cumulative delay that becomes apparent by the time the blastulation stage of embryo development is reached. There is credence in considering this may be due to the need for DNA repair in oocytes originating from patients with increased maternal age causing a prolonged cell cycle. Alternatively, there may be a relationship between the mechanism for blastocyst formation, perhaps linked to compaction, blastocoel formation or cell differentiation that is directly affected by oocyte age. The differences of up to 0.1h increase in blastocyst parameters observed in embryos from older patients here, and supported by others, provide valuable information that could be useful when selecting embryos using ESAs, despite the scientific basis for this delay remaining unknown.

The underlying relationship between maternal BMI and embryo quality is yet to be determined however, there are interesting investigations emerging assessing the composition of follicular fluid from patients with varying BMIs. The effect of BMI seen in this analysis could be due to the requirement for a higher dose of gonadotrophins (33), which has been demonstrated to affect an embryo's morphokinetic profile (2).

The influence of maternal BMI was evident only on t2; a gold standard for embryo viability dating back 20 years (34). Although this effect is not sustained throughout embryo development, the association could be a reflection of embryo viability. For every one-unit increase in BMI, t2 occurs 0.009h (equivalent to 32.4s) earlier. This effect is not likely to be clinically applicable at this stage. It has been demonstrated that patients with increased BMI have reduced pregnancy rates compared to normal BMI patients (33) thus a clinically relevant effect on a morphokinetic parameter, such as t2, is possible. A recent analysis aimed to determine the effect of BMI on the morphokinetics of 5248 embryos. The investigators observed prolonged embryo development to t5 and t8 in obese women when compared to those of normal weight. Embryos from obese women were, on average, 1.60h slower in reaching t5 and 2.23h slower in reaching t8 (35). Conversely, an earlier investigation found no difference in morphokinetics in embryos from obese infertile women compared to normoweight infertile women (36). However, the sample size of this analysis was modest assessing embryos from just 89 patients. It is likely that there is an effect of BMI on an embryo's developmental pattern however future research should be directed to determining this effect specifically in extreme BMIs.

The effect of method of insemination on an embryos morphokinetic profile has been demonstrated previously (4, 37) however, many used an arbitrary time for t0, the most popular of which is time of insemination or injection. The use of these time points as t0 is obviously confounding as they are ambiguous and could vary by hours from oocyte to oocyte. In support of this, differences observed in embryo morphokinetics have been shown to disappear when an observable time point is used for t0 (38, 39). In the current analysis, time of pronuclear fading was used as t0 therefore any observed differences in treatment type are more reliable than those using time of insemination or injection. In particular, those embryos created using ICSI had significantly different t2, tSB, tB, cc2 and tM-tSB values when compared to embryos created through IVF. These significant differences of up to 1.5h indicate that, at the very least, ESAs should be developed to accommodate differing treatment types even when a definable t0 is used, recently corroborated by others (40). There must be further investigations into the more rare treatment types, such as IMSI, P-ICSI or cycles involving oocyte activation to examine the need for alternative optimum ranges for various morphokinetic parameters. With regards to the consideration of treatment type, specifically IVF and ICSI, pertinent to this investigation is the difference in incubator used for fertilisation; those embryos fertilised using ICSI have over 12 hours longer in the controlled environment of an EmbryoScope® compared to those embryos fertilised using standard IVF. This could be considered a confounding variable in this investigation. To control this in future, an incubator shown to have a comparably stable environment to an the TLS device of choice should be utilised or else, in a prospective setting, all embryos should only be incubated in the TLS device post-fertilisation check ensuring embryos are consistently exposed to environmental factors.

The current analysis does not include other suspected confounders such as dose of gonadotrophins, paternal factors, such as age, or endogenous maternal hormone levels, and so is by no means exhaustive. In addition, all embryos that reached tB were included in this analysis. Although this increases the likelihood that the most competent embryos were assessed (i.e. blastocysts), it can be argued that poor embryo quality could have a confounding effect on the morphokinetic parameters

and those that do not have the capacity to reach the blastocyst stage may create bias in the dataset. The analysis serves to demonstrate the effect of certain patient and treatment parameters in order to inform future areas of research and highlight that variability seen in embryo development is not necessarily an effect of embryo viability, as is suggested by those using morphokinetic parameters to predict an embryos ability to implant. This is also an indication regarding the use of ESAs and their inability to be externally applied with the same efficacy as is observed at the development site (23, 24, 39, 41). It is time for embryo selection methods to be developed with variations in patient and treatment parameters in mind. It is vital that any developed embryo selection methods be prospectively applied in randomised controlled trials (RCTs) of adequate sample size and design to eliminate known and unknown confounders. Currently, embryologists select the most viable embryo in a cohort in terms of morphology, morphokinetics and sometimes chromosomal complement and yet implantation still does not occur. This highlights the need for relative as well as objective methods for embryo selection. This fact also highlights an obvious confounder that is often overlooked and is likely to only be able to be controlled through RCTs; endometrial receptivity.

Embryo development is seemingly affected in subtle ways by a multitude of factors. The formulation of ESAs using basic morphokinetic information is not likely to be able to account for the effect of confounders entirely. The differences seen in this analysis appear minimal however, they are significant. These differences are not able to be detected by the human eye and the software currently available for the programming of ESAs built using basic morphokinetic parameters are not sensitive enough to account for these seemingly small variations; this computation can only be achieved through machine learning. Until such a time that appropriate models built with machine learning have been tested in robust trials and subsequently become widely available, it may be beneficial to continue to use macro-morphokinetic markers that are less variable and potentially less heavily influenced by confounding factors. In the first instance, these parameters can be used to perform effective deselection of those embryos undergoing abnormal division events such as direct and reverse cleavage, both shown to reduce implantation potential of embryos (15, 42-44).

## Conclusion

This analysis provides a comprehensive account of the effect of confounding factors on an embryos morphokinetic profile. It highlights the subtle nature of embryo development and the need to perform appropriate and robust production and validation of ESAs if they are to be employed to perform embryo selection in an IVF laboratory. Where some of the rare infertility diagnoses or treatment types are concerned, conclusions should be considered tentative but this analysis provides evidence that further investigations should be carried out to clarify the complex relationships between confounders and morphokinetic parameters. Until the development of embryo selection methods via machine learning that consider the effect of confounders and that have been prospectively applied in RCTs, other macro-morphokinetic markers should be considered to perform simple but effective deselection using time-lapse imaging.


## Acknowledgements

The analyses presented here were carried out using data from The Hewitt Fertility Centre, Liverpool.

## References


1. Armstrong S, Bhide P, Jordan V, Pacey A, Farquhar C. Time-lapse systems for embryo incubation and assessment in assisted reproduction. Cochrane Database Syst Rev. 2018; 5: CD011320
2. Kirkegaard K, Sundvall L, Erlandsen M, Hindkjaer JJ, Knudsen UB, Ingerslev HJ. Timing of human preimplantation embryonic development is confounded by embryo origin. Hum Reprod 2016; 31: 324-31
3. Payne D, Flaherty SP, Barry MF, Matthews CD. Preliminary observations on polar body extrusion and pronuclear formation in human oocytes using time-lapse video cinematography. Hum Reprod 1997; 12: 532-41
4. Lemmen JG, Agerholm I, Ziebe S. Kinetic markers of human embryo quality using time-lapse recordings of IVF/ICSI-fertilized oocytes. Reprod Biomed Online 2008; 17: 385-91
5. Scott L. The origin and consequences of day 2 multinucleation of human embryos. Abstracts of the 26th annual meeting of ESHRE 2010, Rome, Italy, 25: P-204
6. Azzarello A, Hoest T, Mikkelsen AL The impact of pronuclei morphology and dynamicity on live birth outcome after time lapse culture. Hum Reprod 2012; 27: 2649-57
7. Gonzales DS, Pinheiro JC, Bavister BD. Prediction of the developmental potential of hamster embryos in vitro by precise timing of the third cell cycle. J Reprod Fertil 1995; 105: 1-8
8. Ramsing, NB, Cellesen H. Detecting timing and duration of cell divisions by automatic image analysis may improve selection of viable embryos. Fertil Steril 2006; 86 (Suppl): S189
9. Ramsing NB, Berntsen J, Callesen H. Automated detection of cell division and movement in time lapse images of developing bovine embryos can improve selection of viable embryos. Fertil Steril 2007; 88 (Suppl 1): S38
10. Lechniak D, Pers-Kamczyc E, Pawlak P. Timing of the first zygotic cleavage as a marker of developmental potential of mammalian embryos. Reprod Biol 2008; 8: 23-42
11. Herrero J, Tejera A, Ramsing N, Romero JL, Rubio I. Establishing the optimal time ranges of key events during development using time lapse video cinematography. Fertil Steril 2011; 96(Suppl): S102
12. Cruz M, Garrido N, Herrero J, Perez-Cano I, Munoz M, Meseguer M. Timing of cell divisions in human cleavage stage embryos correlates with blastocyst formation and quality. Reprod Biomed Online 2012; 25: 371-81
13. Hlinka D, Kalatova B, Uhrinova I, Dolinska S, Rutarova J, Rezacova J. Time lapse cleavage rating predicts human embryo viability. Physiol Res 2012; 61: 513-25
14. Meseguer M, Rubio I, Cruz M, Basile N, Marcos J, Requena A. Embryo incubation and selection in a time lapse monitoring system improves pregnancy outcome compared with a standard incubator: a retrospective cohort study. Fertil Steril 2012; 98: 1481-9

15. Rubio I, Kuhlmann R, Agerholm I, Kirk J, Herrero J, Escriba MJ et al. Limited implantation success of direct cleaved human zygotes: a time lapse study. Fertil Steril 2012; 98: 1458-63
16. Campbell A, Fishel S, Bowman N, Duffy S, Sedler M, Hickman CF. Modelling a risk classification of aneuploidy in human embryos using non-invasive morphokinetics. Reprod Biomed Online 2013; 26:477–485
17. Wong CC, Loewke KE, Bossert NL, Behr B, De Jonge CJ, Baer TM, Reijo Pera RA. Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage. Nat Biotechnol 2010; 28:1115-21
18. Chamayou S, Patrizio P, Storaci G, Tomaselli V, Alecci C, Ragolia C. et al. The use of morphokinetic parameters to select all embryos with full capacity to implant. J Assist Reprod Genet 2013; 30: 703-10
19. Dal Canto M, Coticchio G, Mignini Renzini M, De Ponti E, Novara PV, Brambillasca F. et al. Cleavage kinetics analysis of human embryos predicts development to blastocyst and implantation. Reprod Biomed Online 2012; 25: 474-80
20. Basile N, Vime P, Florensa M, Aparicio Ruiz B, García Velasco JA, Remohí J, Meseguer M. The use of morphokinetics as a predictor of implantation: a multicentric study to define and validate an algorithm for embryo selection. Hum Reprod 2015; 30: 276-83
21. Petersen BM, Boel M, Montag M, Gardner DK. Development of a generally applicable morphokinetic algorithm capable of predicting the implantation potential of embryos transferred on Day 3. Hum Reprod. 2016; 31: 2231-44
22. Liu Y, Chapple V, Feenan K, Roberts P, Matson P. Time-lapse deselection model for human day 3 in vitro fertilization embryos: the combination of qualitative and quantitative measures of embryo growth. Fertil Steril. 2016; 105: 656-662
23. Kirkegaard K. Time-lapse parameters as predictors of blastocyst development and pregnancy outcome in embryos from good prognosis patients: a prospective cohort study. Hum Reprod 2013; 28: 2643–2651
24. Barrie A, Homburg R, McDowell G, Brown J, Kingsland C, Troup S. Examining the efficacy of six published time-lapse imaging embryo selection algorithms to predict implantation to demonstrate the need for the development of specific, in-house morphokinetic selection algorithms. Fertil Steril 2017; 6 pii: S0015-0282(16)63014-5.
25. Tran D, Cooke S, Illingworth PJ, Gardner DK. Deep learning as a predictive tool for fetal heart pregnancy following time-lapse incubation and blastocyst transfer. Hum Reprod. 2019; 34: 1011–1018
26. VerMilyea M, Hall JMM, Diakiw SM, Johnston A, Nguyen T, Perugini D, Miller A, Picou A, Murphy AP, Perugini M. Development of an artificial intelligence-based assessment model for prediction of embryo viability using static images captured by optical light microscopy during IVF. Hum Reprod. 2020; 35: 770–784
27. Chavez-Badiola A, Farias AFS, Mendizabal-Ruiz G, Garcia-Sanchez R, Drakeley AJ, Garcia-Sandoval JP. Predicting pregnancy test results after embryo transfer by image feature extraction and analysis using machine learning. Sci Rep. 2020; 10: 4394
28. Cutting R, Morroll D, Roberts SA, Pickering S, Rutherford A. Elective single embryo transfer: guidelines for practice British Fertility Society and

Association of Clinical Embryologists; BFS and ACE. Hum Fertil (Camb) 2008; 11: 131-46
29. Ciray HN, Campbell A, Agerholm IE, Aguilar J, Chamayou S, Esbert M, et al. Proposed guidelines on the nomenclature and annotation of dynamic human embryo monitoring by a time lapse user group. Hum Reprod 2014; 29: 2650-60
30. Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, Scott RT Jr. The nature of aneuploidy with increased age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril 2014; 101: 656-63
31. Watcharaseranee N, Ploskonka SD, Goldberg J, Falcone T, Desai N. Does advancing maternal age affect morphokinetic parameters during embryo development? Fertil Steril 2014; 102: e213-14
32. Minasi M, Colsante A, Riccio T, Ruberti A, Casciani V, Scarselli F, Spinella F, Fiorentino F, Varricchio M, Greco E. Correlation between aneuploidy, standard morphology evaluation and morphokinetic development in 1730 biospied blastocysts: a consecutive case series study. Hum Reprod 2016; 31: 2245-54
33. Zander-Fox DL, Henshaw R, Hamilton H, Lane M. Does obesity really matter? The impact of BMI on embryo quality and pregnancy outcomes after IVF in women aged <38 years. Aust N Z J Obstet Gynaecol 2012; 52: 270-6
34. Shoukir Y, Campana A, Farley T, Sakkas D. Early cleavage of in-vitro fertilised human embryos to the 2-cell stage: a novel indicator of embryo quality and viability. Hum Reprod 1997; 12: 1531-6
35. Bartolacci A, Buratini J, Moutier C, Guglielmo MC, Novara PV, Brambillasca F, Renzini MM, Dal Canto M. Maternal body mass index affects embryo morphokinetics: a time-lapse study. J Assist Reprod Genet 2019; 36: 1109-1116
36. Bellver J, Mifsud A, Grau N, Privitera L, Meseguer M. Similar morphokinetic patterns in embryos derived from obese and normoweight infertile women: a time-lapse study. Hum Reprod 2013; 28: 794-800

37. Bodri D, Sugimoto T, Sema JY, Kondo M, Kato R, Kawachiya S, Matsumoto T. Influence of different oocyte insemination techniques on early and late morphokinetic parameters: retrospective analysis of 500 time-lapse monitored blastocysts. Fertil Steril 2015; 104: 1175-81
38. Cruz M, Garrido N, Gadea B, Munoz M, Perez-Cano I, Meseguer M. Oocyte insemination techniques are related to alterations of embryo development timing in an oocyte donation model. Reprod Biomed Online 2013; 27: 367-75
39. Liu Y, Copeland C, Stevens A, Feenan K, Chapple V, Myssonski K, Roberts P, Matson P. Assessment of human embryos by time-lapse videography: A comparison of quantitative and qualitative measures between two independent laboratories. Reprod Biol. 2015; 15: 210-215
40. Fishel S, Campbell A, Montgomery S, Smith R, Nice L, Duffy S, Jenner L, Berrisford K, Kellam L, Smith R, Foad F, Beccles A. Time-lapse imaging algorithms rank human preimplantation embryos according to the probability of live birth. Reprod. Biomed. Online 2018; 37:304-313
41. Freour T, Le Fleuter N, Lammers J, Splingart C, Reignier A, Barriere P. External validation of a time-lapse prediction model. Fertil Steril 2015; 103: 917-22

42. Athayde Wirka K, Chen AA, Conaghan J, Ivani K, Gvakharia M, Behr B, Suraj V, Tan L, Shen S. Atypical embryo phenotypes identified by time lapse microscope: high prevalence and association with embryo development. Fertil Steril 2014; 101: 1637-48
43. Liu Y, Chapple V, Roberts P, Matson P. Prevalence, consequence, and significance of reverse cleavage by human embryos viewed with the use of Embryoscope time lapse video system. Fertil Steril 2014;102: 1295-300
44. Barrie A, Homburg R, McDowell G, Brown J, Kingsland C, Troup S. Preliminary investigation into the prevalence and implantation potential of abnormal phenotypes assessed using time-lapse imaging. Reprod. Biomed. Online 2017. 34: 455-462

| | t2 | | t3 | | t4 | | t5 | | t6 | | t7 | | t8 | | t9 | | tM | | tSB | | tB | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** |
| **Maternal Age** | .007* | -.006 | .050 | -.013 | .007* | -.029 | .791 | -.004 | .809 | .004 | .464 | -.020 | .152 | -.052 | .964 | .001 | .404 | -.029 | .058 | .063 | .043* | .078 |
| **Maternal BMI** | .001* | -.009 | .295 | -.008 | .362 | -.012 | .622 | -.010 | .093 | -.037 | .302 | -.033 | .267 | -0.49 | .330 | -.036 | .305 | -.043 | .133 | -.060 | .272 | -.052 |
| **Suppression** | .573 | -.012 | .613 | -.030 | .251 | -.113 | .754 | 0.47 | .971 | -.006 | .558 | -.144 | .552 | -.199 | .625 | .136 | .577 | .179 | .843 | .060 | .229 | .429 |
| **Infertility Diagnosis** | | | | | | | | | | | | | | | | | | | | | | |
| **Ovarian** | .913 | -.004 | .261 | -.111 | .866 | -.028 | .877 | -.038 | .326 | -.269 | .352 | -.378 | .928 | .050 | .472 | .331 | .863 | -.091 | .437 | .390 | .977 | -.017 |
| **Uterine** | .223 | .045 | .262 | -.119 | .958 | -.009 | .958 | .014 | .716 | -.108 | .662 | .192 | .173 | .809 | .593 | .266 | .494 | .391 | .156 | .768 | .204 | .806 |
| **Donor** | .027* | -.310 | .019* | -.945 | .044* | -1.340 | .168 | -1.388 | .161 | -1.572 | .036* | -3.478 | .230 | -2.698 | .021* | -4.343 | .327 | -2.121 | .238 | -2.419 | .014* | -5.894 |
| **Unexplained** | .571 | -.019 | .968 | .004 | .432 | .123 | .230 | .285 | .558 | .155 | .705 | .148 | .564 | .306 | .485 | .310 | .375 | .454 | .157 | .685 | .254 | .647 |
| **Endocrine** | .103 | -.178 | .802 | .078 | .403 | .432 | .385 | .678 | .216 | 1.077 | .315 | 1.293 | .220 | 2.140 | .713 | .536 | .568 | .960 | .108 | 2.559 | .404 | 1.557 |
| **Secondary** | .002* | -.329 | .418 | -.250 | .263 | -.572 | .746 | -.250 | .184 | -1.143 | .156 | -1.806 | .313 | -1.741 | .668 | -.619 | .013* | -4.137 | .051 | -3.069 | .021* | -4.256 |
| **Treatment Type** | | | | | | | | | | | | | | | | | | | | | | |
| **ICSI** | .001* | -.098 | .281 | .087 | .114 | .211 | .539 | .124 | .245 | .262 | .516 | .216 | .618 | .255 | .990 | .005 | .232 | .520 | .005* | 1.157 | .002* | 1.510 |
| **IMSI** | .306 | -.074 | .377 | .184 | .421 | .277 | .830 | -.112 | .512 | -.381 | .427 | -.682 | .501 | -.783 | .683 | .397 | .009* | 2.938 | .073 | 1.905 | .210 | 1.560 |
| **TESE ICSI** | .435 | -.076 | .462 | .203 | .811 | .110 | .337 | .664 | .275 | .841 | .455 | .851 | .373 | 1.378 | .726 | .453 | .576 | .831 | .050 | 2.769 | .272 | 1.817 |
| **D-IVF** | .084 | .183 | .164 | .422 | .245 | .583 | .107 | 1.222 | .514 | .552 | .090 | 2.121 | .152 | 2.424 | .024* | 3.199 | .407 | 1.353 | .101 | 2.535 | .007* | 4.882 |
| **D-ICSI** | .014* | .341 | .001* | 1.304 | .084 | 1.137 | .008* | 2.650 | .033* | 2.367 | .107 | 2.642 | .248 | 2.571 | .030* | 4.036 | .941 | .160 | .206 | 2.568 | .099 | 3.930 |

Table 1. Multiple regression analysis results for the effect of maternal age, maternal BMI, suppression protocol, infertility diagnosis and treatment type on absolute morphokinetic parameters. Time to two-cell (t2), three-cell (t3), four-cell (t4), five-cell (t5), six-cell (t6), seven-cell (t7), eight-cell (t8), nine-cell (t9), start of compaction (tM), blastulation (tSB) and time to full blastocyst (tB) are included. P-values (P) and beta coefficients (B) are shown for each parameter. Statistically significant results are indicated by *. A negative beta coefficient indicates a decrease in the parameter in hours for every unit increase in the independent variable. BMI; body mass index. ICSI; intra-cytoplasmic sperm injection. IMSI; intra-cytoplasmic morphologically selected sperm injection. TESE; testicular sperm extraction. D-IVF; donor-IVF. D-ICSI; donor-ICSI.

| | cc2 | | cc3 | | cc4 | | s2 | | s3 | | t9-tM | | tM-tSB | | tSB-tB | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** | **P** | **B** |
| **Patient Age** | .285 | -.007 | .094 | .025 | .082 | .053 | .081 | -.016 | .141 | -.048 | .348 | -.031 | <.001* | .092 | .454 | .016 |
| **BMI** | .940 | .001 | .904 | .002 | .726 | .013 | .759 | -.003 | .319 | -.039 | .847 | -.008 | .584 | -.017 | .736 | .009 |
| **Suppression** | .749 | -.018 | .240 | .160 | .236 | .335 | .331 | -.083 | .410 | -.245 | .886 | .043 | .610 | -.119 | .055 | .369 |
| **Infertility Diagnosis** | | | | | | | | | | | | | | | | |
| **Ovarian** | .260 | -.107 | .962 | -.011 | .546 | .381 | .556 | .083 | .858 | .088 | .392 | -.422 | .211 | .481 | .200 | -.407 |
| **Uterine** | .108 | -.164 | .924 | .023 | .279 | -.543 | .470 | .110 | .134 | .795 | .814 | .125 | .363 | .377 | .912 | .038 |
| **Unexplained** | .805 | .023 | .456 | .162 | .993 | .004 | .380 | .120 | .964 | .021 | .763 | .143 | .534 | .231 | .902 | -.038 |
| **Donor*** | .102 | -.635 | .958 | -.048 | .387 | -1.645 | .494 | -.394 | .514 | -1.309 | .271 | 2.222 | .850 | -.298 | .007* | -3.475 |
| **Endocrine*** | .394 | .256 | .730 | .246 | .277 | -1.604 | .430 | .354 | .348 | 1.462 | .787 | .424 | .190 | 1.599 | .319 | -1.002 |
| **Secondary*** | .052 | -.579 | .648 | .322 | .441 | 1.122 | .467 | -.322 | .333 | -1.491 | .023* | -3.518 | .375 | 1.068 | .232 | -1.188 |
| **Treatment Type** | | | | | | | | | | | | | | | | |
| **ICSI** | .018* | .185 | .636 | -.087 | .564 | -.220 | .283 | .124 | .802 | .101 | .203 | .515 | .044* | .637 | .175 | .353 |
| **IMSI^** | .198 | .258 | .413 | -.389 | .230 | 1.180 | .755 | .093 | .518 | -.671 | .015* | 2.541 | .204 | -1.033 | .606 | -.346 |
| **TESE ICSI^** | .296 | .279 | .380 | .555 | .479 | -.924 | .813 | -.094 | .605 | .714 | .785 | .377 | .073 | 1.938 | .285 | -.952 |
| **D-IVF^** | .414 | .239 | .355 | .639 | .588 | .776 | .711 | .161 | .427 | 1.201 | .224 | -1.846 | .318 | 1.182 | .016* | 2.348 |
| **D-ICSI^** | .012* | .963 | .096 | 1.513 | .436 | 1.465 | .770 | -.167 | .968 | -.079 | .052 | -3.876 | .121 | 2.408 | .288 | 1.362 |

Table 2. Multiple regression analysis results for the effect of maternal age, maternal BMI, suppression protocol, infertility diagnosis and treatment type on interval morphokinetic parameters. Duration of second cell cycle (cc2; t3-t2), third cell cycle (cc3; t5-t4), fourth cell cycle (cc4; t9-t8), synchrony of the second cell cycle (s2; t3-t4), synchrony of the third cell cycle (s3; t8-t5), time between t9 and tM, time between tM and tSB, time between tSB and tB are included. P-values (P) and beta coefficients (B) are shown for each parameter. Statistically significant results are indicated by *. A negative beta coefficient indicates a decrease in the parameter in hours for every unit increase in the independent variable. ^ indicates reduced sample size (<20 patients included). BMI; body mass index. ICSI; intra-cytoplasmic sperm injection. IMSI; intra-cytoplasmic morphologically selected sperm injection. TESE; testicular sperm extraction. D-IVF; donor-IVF. D-ICSI; donor-ICSI.

| Number of embryos | 2376 |
|---|---|
| **Number of patients** | 639 |
| **Number of cycles** | 639 |
| **Maternal age (mean +/- SD)** | 32.9 +/- 4.4 |
| **Maternal BMI (mean +/- SD)** | 24.3 +/- 3.7 |
| **Suppression protocol (n / %)** | |
| Agonist | 275 / 41% |
| Antagonist | 364 / 59% |
| **Cause of infertility (n / %)** | |
| Male factor | 225 / 35.2% |
| Ovarian | 114 / 17.8% |
| Uterine | 88 / 13.8% |
| Unexplained | 193 / 30.2% |
| Donor^ | 4 / 0.6% |
| Endocrine^ | 8 / 1.3% |
| Secondary^ | 7 / 1.1% |
| **Treatment Type (n / %)** | |
| IVF | 343 / 53.7% |
| ICSI | 266 / 41.6% |
| IMSI^ | 17 / 2.7% |
| TESE-ICSI^ | 7 / 1.1% |
| D-IVF^ | 4 / 0.6% |
| D-ICSI^ | 2 / 0.3% |
| **Number of eggs collected (mean +/- SD)** | 14.7 +/- 7.3 |
| **Number of embryo transfers** | 503 |
| **Number of embryos transferred** | 550 |
| **Number of positive pregnancy tests (n / BPR)** | 213 / 42.3% |
| **Number of fetal hearts (n / IR)** | 219 / 39.8% |

Table 3. Baseline patient information for the analysed embryo cohort. ^ indicates reduced sample size (<20 patients included). SD; standard deviation. BMI; body mass index. IVF; in vitro fertilization. ICSI; intra-cytoplasmic sperm injection. IMSI; intra-cytoplasmic morphologically selected sperm injection. TESE; testicular sperm extraction. D-IVF; donor-IVF. D-ICSI; donor-ICSI. BPR; biochemcical pregnancy rate (number of positive hCG tests/number of embryo transfers). IR; implantation rate (number of fetal hearts/ number of embryos transferred).